According to the lawsuit, the IPO documents and defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- Lomecel-B, a cell-based therapy product which is derived from culture-expanded medicinal signaling cells that are sourced from the bone marrow of young healthy adult donors, was not as effective in treating aging frailty as defendants had led investors to believe;
- accordingly, Lomecel-B’s clinical and commercial prospects with respect to aging frailty were overstated;
- as a result of all the foregoing, Longeveron’s financial and business prospects were also overstated;
- and as a result, the Company’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
